Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda

Background: The frequency of HIV dementia in a recent study of HIV+ individuals at the Infectious Disease Institute in Kampala, Uganda, was 31%. Coformulated generic drugs, which include stavudine, are the most common regimens to treat HIV infection in Uganda and many other parts of Africa. Objective: To evaluate the benefits and risks of stavudine-based highly active antiretroviral therapy (HAART) for HIV-associated cognitive impairment and distal sensory neuropathy. The study compared neuropsychological performance changes in HIV+ individuals initiating HAART for 6 months and HIV− individuals receiving no treatment for 6 months. The risk of antiretroviral toxic neuropathy as a result of the initiation of stavudine-based HAART was also examined. Methods: At baseline, 102 HIV+ individuals in Uganda received neurologic, neuropsychological, and functional assessments; began HAART; and were followed up for 6 months. Twenty-five HIV− individuals received identical clinical assessments and were followed up for 6 months. Results: In HIV+ individuals, there was improvement in verbal memory, motor and psychomotor speed, executive thinking, and verbal fluency. After adjusting for differences in sex, HIV+ individuals demonstrated significant improvement in the Color Trails 2 test (p = 0.025) compared with HIV− individuals. Symptoms of neuropathy developed in 38% of previously asymptomatic HIV+ patients after initiation of the stavudine-based HAART. Conclusions: After the initiation of highly active antiretroviral therapy (HAART) including stavudine, HIV+ individuals with cognitive impairment improve significantly as demonstrated by improved performance on a test of executive function. However, peripheral neurotoxicity occurred in 30 patients, presumably because of stavudine-based HAART, suggesting the need for less toxic therapy.

[1]  N. McGrath,et al.  FREQUENCY OF AND RISK FACTORS FOR HIV DEMENTIA IN AN HIV CLINIC IN SUB-SAHARAN AFRICA , 2007, Neurology.

[2]  N. Nakasujja,et al.  Antiretroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa , 2006, Neurology.

[3]  O. Selnes,et al.  The International HIV Dementia Scale: a new rapid screening test for HIV dementia , 2005, AIDS.

[4]  C. Hall,et al.  Highly Active Antiretroviral Therapy Improves Neurocognitive Functioning , 2004, Journal of acquired immune deficiency syndromes.

[5]  N. Sacktor.  The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. , 2002, Journal of neurovirology.

[6]  K. Marder,et al.  Incidence of and risk factors for HIV-associated distal sensory polyneuropathy , 2002, Neurology.

[7]  T. Quinn.  The academic alliance for AIDS care and prevention in Africa. , 2001, The Hopkins HIV report : a bimonthly newsletter for healthcare providers.

[8]  A. Sönnerborg,et al.  Antiretroviral therapy may improve sensory function in HIV-infected patients , 2000, Neurology.

[9]  N M Laird,et al.  Generalized linear mixture models for handling nonignorable dropouts in longitudinal studies. , 2000, Biostatistics.

[10]  O. Selnes,et al.  Combination antiretroviral therapy improves psychomotor speed performance in HIV-seropositive homosexual men , 1999, Neurology.

[11]  P. Albert,et al.  Models for longitudinal data: a generalized estimating equation approach. , 1988, Biometrics.

[12]  L. Prockop.  AIDS dementia complex. , 1988, The Journal of legal medicine.

[13]  D. Holtzman,et al.  Peripheral neuropathy associated with acquired immunodeficiency syndrome. Prevalence and clinical features from a population-based survey. , 1988, Archives of neurology.

[14]  R. Schooley,et al.  Peripheral neuropathy in the acquired immunodeficiency syndrome , 1988, Annals of neurology.

[15]  D. Karnofsky,et al.  The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma , 1948 .

[16]  O. Selnes,et al.  Improvement in HIV-associated motor slowing after antiretroviral therapy including protease inhibitors. , 2000, Journal of neurovirology.

[17]  Peter Piot,et al.  Joint United Nations Program on HIV/AIDS (UNAIDS) , 1997 .

[18]  M. Maj,et al.  WHO Neuropsychiatric AIDS study, cross-sectional phase II. Neuropsychological and neurological findings. , 1994, Archives of general psychiatry.